Drugstores

Biogen Idec Inc. and Genentech Inc. remain in dispute with Sanofi- Aventis Deutschland GmbH over the alleged infringement of U.S. Patents 5,849,522 and 6,218,140.

Both patents relate to enhancers for eukaryotic…

Genentech Inc. continues to be involved in an arbitration proceeding filed by Hoechst GmbH seeking royalties, according to Biogen Idec Inc.’s latest Quarterly Report filed with the U.S. Securities and…

The U.S. Court of Appeals for the Federal Circuit has yet to rule on Classen Immunotherapies Inc.’s appeal from the dismissal of its patent infringement suit against Biogen Idec Inc,…